Advertisement

Beta-Blocker Seems to Improve Outcomes in Septic Shock — Physician’s First Watch

Medical News |
October 10, 2013

Beta-Blocker Seems to Improve Outcomes in Septic Shock

By Joe Elia

Use of esmolol, a short-acting beta-blocker, stabilizes heart rates and improves outcomes in patients with septic shock and increased heart rates, according to a phase II trial in JAMA.

Researchers randomized some 150 patients either to continuous infusion of esmolol or usual care for the length of their stay in the ICU. At study entry, all had heart rates of at least 95/min.

Throughout their stays, the esmolol recipients maintained heart rates between 80 and 94, which were significantly lower than among controls. The esmolol group also maintained target mean arterial pressure despite a marked reduction in need for norepinephrine. Mortality at 28 days was 49% with esmolol and 81% with usual care.

An editorialist reminds readers that beta-blockers are not without risks of their own, and he calls for trials to define the group of patients most likely to benefit from their use in these circumstances.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement